Nomura Holdings’s Castle Biosciences CSTL Stock Holding History

Nomura Holdings’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,748	Closed	-$878K	–	1852
2026 Q1	$878K	Buy	+35,748	New	+$1.17M	﹤0.01%	1206

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's CSTL Position: Q2 2026 in Review

Nomura Holdings sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 35,748 shares — an estimated $878K sold.

Nomura Holdings first reported a position in CSTL in Q1 2026 and held it in 1 quarter. The position peaked at $878K in Q1 2026. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Nomura Holdings reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 35,748 Castle Biosciences shares in Q2 2026, an estimated $878K.
Nomura Holdings first reported a position in Castle Biosciences in Q1 2026 and held it in 1 quarter.
Nomura Holdings's Castle Biosciences position peaked at $878K in Q1 2026.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.